$BCLI
Brainstorm Cell Therapeutics Inc Stock $bcli

$bcli Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000114420418055650 Filed on October 29, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2018 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.580M	$1.260M	$1.610M
YoY Change	18.8%	3.28%	151.56%
% of Gross Profit
Research & Development	$3.860M	$1.975M	$1.480M
YoY Change	-345.86%	69.09%	240.23%
% of Gross Profit
Depreciation & Amortization	$20.00K	$33.00K	$31.00K
YoY Change	-33.33%	43.48%	72.22%
% of Gross Profit
Operating Expenses	$5.440M	$1.975M	$3.090M
YoY Change	-2366.67%	69.09%	610.34%
Operating Profit		-$3.232M	-$3.087M
YoY Change		35.12%	187.16%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$50.00K	$60.00K	$0.00
YoY Change	25.0%	-700.0%	-100.0%
Pretax Income	-$5.380M	-$3.180M	-$3.090M
YoY Change	-2021.43%	32.5%	197.12%
Income Tax
% Of Pretax Income
Net Earnings	-$5.380M	-$3.176M	-$3.090M
YoY Change	-2021.43%	32.17%	197.12%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$259.5K	-$153.7K	-$158.4K
COMMON SHARES
Basic Shares Outstanding	20.71M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.060M	$10.89M	$17.44M
YoY Change	-9.02%	3.22%	159.52%
Cash & Equivalents	$942.0K	$697.0K	$2.262M
Short-Term Investments	$6.120M	$10.19M	$15.18M
Other Short-Term Assets	$1.190M	$1.240M	$1.160M
YoY Change	-0.83%	1277.78%	404.35%
Inventory
Prepaid Expenses	$1.103M	$1.103M	$1.103M
Receivables	$2.010M	$490.0K	$960.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$10.27M	$12.62M	$19.56M
YoY Change	6.72%	15.26%	154.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$651.0K	$564.0K	$600.0K
YoY Change	66.07%	56.67%	100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$958.0K	$1.148M	$860.0K
YoY Change	-46.78%	3726.67%	4200.0%
Total Long-Term Assets	$958.0K	$1.148M	$1.460M
YoY Change	-46.78%	194.36%	356.25%
TOTAL ASSETS
Total Short-Term Assets	$10.27M	$12.62M	$19.56M
Total Long-Term Assets	$958.0K	$1.148M	$1.460M
Total Assets	$11.23M	$13.77M	$21.02M
YoY Change	-1.71%	21.42%	162.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.548M	$2.602M	$4.180M
YoY Change	219.38%	829.29%	1717.39%
Accrued Expenses	$1.042M	$428.0K	$1.470M
YoY Change	27.54%	114.0%	1189.47%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.212M	$3.791M	$8.150M
YoY Change	12.07%	-38.26%	1046.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.212M	$3.791M	$8.150M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$6.212M	$3.791M	$8.150M
YoY Change	12.07%	-38.26%	1047.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$94.02M	-$88.64M
YoY Change	17.42%
Common Stock	$94.63M	$94.21M
YoY Change	10.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.016M	$9.978M	$12.87M
YoY Change
Total Liabilities & Shareholders Equity	$11.23M	$13.77M	$21.02M
YoY Change	-1.71%	21.42%	162.75%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2018 Q2
OPERATING ACTIVITIES
Net Income	-$5.380M	-$3.176M	-$3.090M
YoY Change	-2021.43%	32.17%	197.12%
Depreciation, Depletion And Amortization	$20.00K	$33.00K	$31.00K
YoY Change	-33.33%	43.48%	72.22%
Cash From Operating Activities	-$3.720M	-$6.594M	$55.00K
YoY Change	26.96%	-271.58%	-103.37%
INVESTING ACTIVITIES
Capital Expenditures	-$110.0K	$1.000K	$215.0K
YoY Change	83.33%	-98.84%	571.88%
Acquisitions
YoY Change
Other Investing Activities	$4.080M	$4.980M	-$12.82M
YoY Change	45.2%	-169.65%	-288.25%
Cash From Investing Activities	$3.970M	$4.983M	-$13.03M
YoY Change	44.36%	-168.84%	-292.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$46.00K	$11.99M
YoY Change	-100.0%	-38.67%	39880.0%
NET CHANGE
Cash From Operating Activities	-3.720M	-$6.594M	$55.00K
Cash From Investing Activities	3.970M	$4.983M	-$13.03M
Cash From Financing Activities	0.000	$46.00K	$11.99M
Net Change In Cash	250.0K	-$1.565M	-$984.0K
YoY Change	1150.0%	-52.86%	-119.0%
FREE CASH FLOW
Cash From Operating Activities	-$3.720M	-$6.594M	$55.00K
Capital Expenditures	-$110.0K	$1.000K	$215.0K
Free Cash Flow	-$3.610M	-$6.595M	-$160.0K
YoY Change	25.78%	-275.54%	-90.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	697000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2483000	USD
CY2018Q3	us-gaap	Short Term Investments ShortTermInvestments	10194000	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	5273000	USD
CY2018Q3	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	492000	USD
CY2017Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	672000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1238000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1195000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	12621000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	9623000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	584000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1408000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	564000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	392000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1148000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1800000	USD
CY2018Q3	us-gaap	Assets Assets	13769000	USD
CY2017Q4	us-gaap	Assets Assets	11423000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2602000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1424000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	428000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	817000	USD
CY2018Q3	bcli	Deferred Grant Income DeferredGrantIncome	130000	USD
CY2017Q4	bcli	Deferred Grant Income DeferredGrantIncome	2625000	USD
CY2018Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	631000	USD
CY2017Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	677000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3791000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5543000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	3791000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	5543000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	94199000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	85944000	USD
CY2018Q3	bcli	Receipts On Account Of Shares ReceiptsOnAccountOfShares	4408000	USD
CY2017Q4	bcli	Receipts On Account Of Shares ReceiptsOnAccountOfShares	0	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-88640000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-80075000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13769000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11423000	USD
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20700713	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18976169	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20700713	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18976169	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4433000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2544000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1975000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1168000	USD
CY2017Q3	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	11000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8565000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5228000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4193000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2693000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1257000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1224000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8626000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5237000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3232000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2392000	USD
	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	-61000	USD
	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	-9000	USD
CY2018Q3	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	-56000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-3176000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-2403000	USD
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.43
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.28
CY2018Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.15
CY2017Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.13
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19754159	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18737307	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20691900	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18783997	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	9902000	USD
CY2017	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	62000	USD
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	554000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	209000	USD
CY2017	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	105000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-4952000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	5880000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	0	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	598000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	25000	USD
	bcli	Stock Issued During Periodvalueexercise And Reissuance Of Warrants StockIssuedDuringPeriodvalueexerciseAndReissuanceOfWarrants	12040000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	9978000	USD
	us-gaap	Depreciation Depreciation	89000	USD
	us-gaap	Depreciation Depreciation	57000	USD
CY2018Q3	us-gaap	Depreciation Depreciation	33000	USD
CY2017Q3	us-gaap	Depreciation Depreciation	23000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	18000	USD
CY2018Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2017Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	18000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	598000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	398000	USD
CY2018Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	235000	USD
CY2017Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	215000	USD
	bcli	Increase Decrease In Accounts Receivable And Prepaid Expenses IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses	-965000	USD
	bcli	Increase Decrease In Accounts Receivable And Prepaid Expenses IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses	-50000	USD
CY2018Q3	bcli	Increase Decrease In Accounts Receivable And Prepaid Expenses IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses	-670000	USD
CY2017Q3	bcli	Increase Decrease In Accounts Receivable And Prepaid Expenses IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses	-561000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1178000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-70000	USD
CY2018Q3	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1580000	USD
CY2017Q3	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	48000	USD
	bcli	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	-2495000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1241000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4983000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7238000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	25000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	105000	USD
CY2018Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2017Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	75000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	12040000	USD
	bcli	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	5250000	USD
CY2018Q3	bcli	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	-1755000	USD
CY2017Q3	bcli	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	5250000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-435000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	96000	USD
CY2018Q3	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1021000	USD
CY2017Q3	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	131000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8665000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	571000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6594000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3843000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	261000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	118000	USD
CY2018Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000	USD
CY2017Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	86000	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	4921000	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-1360000	USD
CY2018Q3	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-4983000	USD
CY2017Q3	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	7150000	USD
	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	4000	USD
	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	1000	USD
CY2018Q3	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	-1000	USD
CY2017Q3	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	2000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5186000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2018Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	46000	USD
CY2017Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12065000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	105000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	75000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1786000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1917000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1565000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3320000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	547000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2262000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5784000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2464000	USD
	bcli	Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus	P15Y
	us-gaap	Maturity Of Time Deposits MaturityOfTimeDeposits	P12M
CY2017	us-gaap	Maturity Of Time Deposits MaturityOfTimeDeposits	P12M
CY2018Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1103000	USD
CY2018Q3	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	551000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1103000	USD
CY2017Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	1378000	USD
CY2017Q3	us-gaap	Grants Receivable GrantsReceivable	15912000	USD
	us-gaap	Proceeds From Grantors ProceedsFromGrantors	9050000	USD
CY2017	us-gaap	Proceeds From Grantors ProceedsFromGrantors	7050000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	4495000	USD
CY2017	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	4425000	USD
CY2018Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	11994000	USD
CY2018Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	899999	shares
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	59000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	416000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	598000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:left;"><table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 56.7pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"> </div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 28.35pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">D.</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of estimates</div></div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1.18in; margin-top: 0px; text-align: justify; text-indent: -0.39in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 1.18in;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	2805	shares
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	BRAINSTORM CELL THERAPEUTICS INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001137883
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Trading Symbol TradingSymbol	BCLI
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20707237	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	true

Files In Submission

Name	View Source	Status
0001144204-18-055650-index-headers.html	Edgar Link	pending
0001144204-18-055650-index.html	Edgar Link	pending
0001144204-18-055650.txt	Edgar Link	pending
0001144204-18-055650-xbrl.zip	Edgar Link	pending
bcli-20180930.xml	Edgar Link	completed
bcli-20180930.xsd	Edgar Link	pending
bcli-20180930_cal.xml	Edgar Link	unprocessable
bcli-20180930_def.xml	Edgar Link	unprocessable
bcli-20180930_lab.xml	Edgar Link	unprocessable
bcli-20180930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv505023_10q.htm	Edgar Link	pending
tv505023_ex31-1.htm	Edgar Link	pending
tv505023_ex31-2.htm	Edgar Link	pending
tv505023_ex32-1.htm	Edgar Link	pending
tv505023_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCLI
Brainstorm Cell Therapeutics Inc Stock $bcli

2018 Q4 Form 10-Q Financial Statement

#000114420418055650 Filed on October 29, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI Brainstorm Cell Therapeutics Inc Stock $bcli

2018 Q4 Form 10-Q Financial Statement

#000114420418055650 Filed on October 29, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI
Brainstorm Cell Therapeutics Inc Stock $bcli